Week in Review: DXY Raises $500 Million for Online Consumer Healthcare Site

Deals and Financings   DXY, a China healthcare platform, raised $500 million in an E round to continue expanding its online MD-support site into consumer healthcare; Beijing 's Oceanpine Capital closed its Fund II with $400 million for China-US investments in advanced technology, including biopharmas; Medbanks Network Technology completed a $305 million Series E1 round for oncology big data medical and healthcare services; Shanghai 's Zai Lab in-licensed China rights to a next-gen inhibitor of mutant EGFR variants in a $233 million deal; Synyi AI, a Shanghai company that offers artificial intelligence technology for medical treatment, closed a $61 million Series D round; Shenzhen ImmVira completed a Series C financing of undisclosed size to support its oncolytic virus and vector delivered candidates; COVID-19 Pandemic A Sinopharm inactivated virus COVID-19 vaccine was 79% effective in a Phase III test; Shanghai Fosun Pharma will form a JV with its German partner BioNTech to manufacture mRNA COVID-19 vaccine in China ; Government and Regulatory China added 119 new therapies to its National Reimbursement Drug List after domestic and global drugmakers accepted price reductions averaging 51%; Trials and Approvals Hutchison China MediTech (Chi-Med) announced surufatinib was approved in China to treat non-pancreatic neuroendocrine tumors; Beijing InnoCare Pharma reported China 's NMPA approved its BTK inhibitor for three indications in leukemia and lymphoma; Ascletis of Hangzhou announced its Gannex subsidiary dosed the first person in a US Phase I trial of ASC42, its NASH treatment. Stock Symbols: (NSDQ: ZLAB; HK: 9688) (SHA: 600196; HK: 02196) (NSDQ/AIM: HCM) (HK: 09969) (HK: 1672) Share this with colleagues: // //